Belite

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Retrieved on: 
Lundi, mai 6, 2024
Stargardt disease, University, Bias, Westmead, Stargardt, Research, Geographic atrophy, DRAGON, Adolescence, Growth, Observation, Disease, Therapy, Retina, Dry, Patient, Classification, CSO, Genotype, ABCA4, Annual general meeting, Belite, ARVO, SAN, Visual acuity, Pharmaceutical industry

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).

Key Points: 
  • Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).
  • Genetic profiling was performed on the 13 adolescent STGD1 patients enrolled in a Phase 2 study of Tinlarebant.
  • “Data from the genotype and lesion growth analyses from our completed Phase 2 trial continues to demonstrate the efficacy of Tinlarebant,” said Dr. Nathan Mata, CSO of Belite Bio.
  • The presentation is now available in the “Presentations & Events” section of Belite Bio’s website: https://investors.belitebio.com/presentations-events/events.

Belite Bio to Participate in the BTIG Ophthalmology Day

Retrieved on: 
Lundi, novembre 20, 2023
Retina, Belite, Therapy, Ophthalmology, SAN

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m.

Key Points: 
  • SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m.
  • ET.
  • The Belite management team will be participating in one-on-one meetings at the event.
  • Investors interested in meeting with Belite at the conference should contact their BTIG representative.

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

Retrieved on: 
Jeudi, mai 4, 2023
Therapy, MB, Stargardt disease, UCL Institute of Ophthalmology, RBP4, Stargardt, Bachelor of Science, Belite, Moorfields Eye Hospital, Royal College of Ophthalmologists, Patient, MB BS, Adolescence, FACS, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a virtual Key Opinion Leader event on focusing on adolescent patients with Stargardt disease (STGD1) on Wednesday, May 10, 2023 at 1:00 PM Eastern Time.

Key Points: 
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (Moorfields Eye Hospital and UCL Institute of Ophthalmology) who will discuss progression of childhood-onset STGD1 and Belite Bio’s Phase 2 study evaluating the safety and efficacy of Tinlarebant (LBS-008) in adolescent STGD1 patients.
  • Tinlarebant (LBS-008) is an oral, once daily RBP4 antagonist designed to reduce the accumulation of ocular vitamin-A based toxins which have been implicated in the onset and progression of STGD1.
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S. and Europe for the treatment of STGD1.
  • A live question and answer session will follow the formal presentations.

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Retrieved on: 
Mardi, avril 11, 2023
Stem cell, IOB, University, Johns Hopkins Hospital, Wilmer Ophthalmological Institute, Stargardt disease, Johns Hopkins School of Medicine, Geographic atrophy, RBP4, Vitamin A, Retina, Belite, Medical school, Moorfields Eye Hospital, Professor, Principal, University of Basel, Society, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical need, today announced it will host a virtual key opinion leader (KOL) event to discuss the RBP4 antagonist tinlarebant and its relevance in the treatment of Stargardt Disease 1.

Key Points: 
  • (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).
  • Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.
  • He completed residency at Tübingen’s University Eye Hospital prior to a fellowship at Moorfields Eye Hospital & Institute of Ophthalmology in London.
  • A replay will be available approximately two hours after the event for 90 days.

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Retrieved on: 
Mardi, juillet 19, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Stanford University School of Medicine, NIH, Instagram, Eye, Vance DeGeneres, DRAGON, Edward, Clinical trial, Company, Visual impairment, LinkedIn, Stargardt disease, Columbia University, United Kingdom, Vitamin A, Retina, U.S. Securities and Exchange Commission, HIV disease progression rates, Belite, IND, GLOBE, Twitter, Food, CEO, Lists of diseases, Safety, Quality of life, Severe cognitive impairment, Facebook, RBP4, Disease, FDA, ABCA4, Treatment, AMD, ODD, RPD, Efficacy, NASDAQ, Pediatrics, Master of Science, Investigational New Drug, Patient, Adolescence, Pharmaceutical industry, Medicine, Ophthalmology, MD

Belite Bio is currently conducting a 2-year Phase 2 trial and a 2-year Phase 3 trial of LBS-008 in adolescent STGD1 subjects.

Key Points: 
  • Belite Bio is currently conducting a 2-year Phase 2 trial and a 2-year Phase 3 trial of LBS-008 in adolescent STGD1 subjects.
  • The Phase 2 trial, which has enrolled 13 subjects at clinical sites in Australia and Taiwan, was initiated immediately following the successful completion of a Phase 1b dose-finding trial in the same adolescent STGD1 patients.
  • Belite Bios compelling clinical data to date has shown trends for stabilization or improvement of vision in adolescent STGD1 subjects.
  • Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.